Interleukin‐1 blockade with anakinra in acute leukaemia patients with severe COVID‐19 pneumonia appears safe and may result in clinical improvement

Lignende værker

• Interleukin‐6 blockade treatment for COVID‐19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia
  af: Ranger, Amita, et al.
  Udgivet: (2020)
• Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study
  af: Bozzi, Giorgio, et al.
  Udgivet: (2021)
• Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES)
  af: Stredny, Coral M., et al.
  Udgivet: (2020)
• Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1‐mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID‐19 pandemic
  af: Farah, Nadine, et al.
  Udgivet: (2020)
• Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia
  af: Pontali, Emanuele, et al.
  Udgivet: (2021)